Clinical Trials on Anemia in Myelodysplastic Syndromes in United Kingdom

Total 1974 results

Sumitomo Pharma America, Inc.

Terminated

A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

Anemia in Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Patients With Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia With Ringed...

United States
Brian Jonas
Pharmacyclics LLC.

Completed

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Refractory Anemia With Excess Blasts in Transformation

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia...

United States
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

Unspecified Childhood Solid Tumor, Protocol Specific | Childhood Myelodysplastic Syndromes | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With... and other conditions

United States
Silence Therapeutics plc

Withdrawn

Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

Non-transfusion-dependent Thalassemia | Low Risk Myelodysplastic Syndrome

United Kingdom, Bulgaria
King's College Hospital NHS Trust

Completed

King's Invasive Aspergillosis Study II

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Bone Marrow Transplantation | Aplastic Anemia

United Kingdom
Masonic Cancer Center, University of Minnesota

Recruiting

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Myelodysplastic Syndromes | Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Myeloid Leukemia | Secondary Myelodysplastic Syndrome and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Aplastic Anemia | de Novo Myelodysplastic Syndrome

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome

Severe Aplastic Anemia (SAA) | Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)

United States
National Cancer Institute (NCI)

Completed

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in Transformation

United States
BioLineRx, Ltd.

Completed

Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome

Aplastic Anemia | Hypoplastic Myelodysplastic Syndrome

United States
Silence Therapeutics plc

Completed

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Non-transfusion-dependent Thalassemia | Low Risk Myelodysplastic Syndrome | Very-Low Risk Myelodysplastic Syndrome

Thailand, Israel, Jordan, United Kingdom, Germany, Italy, Malaysia
University College, London
Medical Research Council

Recruiting

Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation (ToTem)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myeloma | Graft Vs Host Disease | Severe Aplastic Anemia | Primary Immune Deficiency

United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Previously Treated Myelodysplastic Syndrome | Fanconi Anemia | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia in Remission

United States, Brazil
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

MDS (Myelodysplastic Syndrome) | Severe Aplastic Anemia

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Aplastic Anemia

United States
Fred Hutchinson Cancer Center
Jazz Pharmaceuticals

Terminated

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 | Myeloid Neoplasm

United States
Case Comprehensive Cancer Center

Completed

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Thrombocytopenia | Chronic Myelomonocytic Leukemia | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Ringed Sideroblasts

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland

Completed

Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United Kingdom
Roswell Park Cancer Institute

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Alkylating Agent-Related Acute Myeloid Leukemia | Refractory Anemia With Excess Blasts in Transformation

United States
National Institutes of Health Clinical Center (CC)

Completed

Leucovorin for the Treatment of 5 q Minus Syndrome

Myelodysplastic Syndrome | 5q Minus Syndrome

United States
Dana-Farber Cancer Institute
National Institutes of Health (NIH); Brigham and Women's Hospital

Completed

Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts

United States
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

Myelodysplastic Syndrome (MDS) | Severe Aplastic Anemia | Hypo-Plastic MDS

United States
Eric Stephen Winer, MD

Recruiting

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

United States
Anjali Sharathkumar
Amgen

Active, not recruiting

TPO-Mimetic Use in Children for Hematopoietic Failure

Thrombocytopenia | Bone Marrow Failure Disorders | Aplastic Anemia | Refractory Cytopenia of Childhood | Myelodysplastic Syndrome(MDS)

United States
London North West Healthcare NHS Trust

Unknown

Bowel Preparation and Prokinetics in Capsule Endoscopy

Gastrointestinal Hemorrhage | Small Bowel Disease | Refractory Anemia

United Kingdom
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia in Remission | Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Previously Treated Myelodysplastic Syndromes | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess...

United States
Onconova Therapeutics, Inc.

Terminated

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

Myelodysplastic Syndrome | MDS | Refractory Anemia With Excess Blasts | RAEB

United States, Spain, Canada, France, Australia, Switzerland, Israel, Japan, Belgium, India, Ireland, United Kingdom, Croatia, Czechia, Poland, Estonia, Germany, Italy, Austria, Hungary, Russian Federation, Sweden
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Myelodysplastic Syndromes

Israel, United States, Korea, Republic of, Australia, France, Germany, Spain, United Kingdom, Czechia, Austria, Italy, Greece, Poland
Shield Therapeutics
Medpace, Inc.

Completed

Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency

Iron Deficiency, Anaemia in Children | Iron-Deficiency

United Kingdom
Celgene
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...

Completed

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

Myelodysplastic Syndromes

Canada, United States, Germany, Belgium, France, United Kingdom, Turkey, Spain, Italy, Netherlands, Sweden
Eleos, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Terminated

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); National Institute of Allergy and Infectious... and other collaborators

Recruiting

Safety Study of Cord Blood Units for Stem Cell Transplants

Lymphoma | Leukemia | Aplastic Anemia | Myelodysplastic Syndrome (MDS)

United States
IGF Oncology, LLC

Terminated

IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic | Anemia, Refractory, With Excess of Blasts

United States
Fallon Clinic

Completed

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Anemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia in Remission | Refractory Anemia With Excess Blasts | Refractory... and other conditions

United States
Children's Hospital of Philadelphia
National Cancer Institute (NCI); University of Pennsylvania; City of Hope Medical... and other collaborators

Recruiting

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors (IAMFIT)

Myelodysplastic Syndromes | Aplastic Anemia | Lymphoblastic Leukemia | Cancer Survivors

United States
Celgene

Completed

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q (MDS-005)

Anemia

United States, Belgium, Spain, United Kingdom, Austria, Canada, Germany, Portugal, France, Australia, Israel, Japan, Italy, Czechia, Poland, Turkey
Emory University

Withdrawn

Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study

Hematopoietic and Lymphoid Cell Neoplasm | Leukemia | Anemia | Myelodysplastic Syndrome | Aplastic Anemia | Bone Marrow Failure

United States
Roswell Park Cancer Institute
Celldex Therapeutics

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Refractory Anemia | Blasts 30 Percent or Less of Bone Marrow Nucleated Cells

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and...

Terminated

Study of Velcade and Thalidomide in Patients With Myelodysplasia

Myelodysplastic Syndrome

United States
Jason Robert Gotlib
Celgene Corporation

Terminated

Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia

Leukemia | Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Celgene

Recruiting

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome With Excess Blasts | IDH2 Gene Mutation | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 20-30 Percent of Bone Marrow Nucleated Cells

United States
St. Bartholomew's Hospital

Unknown

Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United Kingdom
M.D. Anderson Cancer Center

Recruiting

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Myelodysplastic Syndromes | Myeloproliferative Chronic Myelomonocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Childhood Acute Erythroleukemia (M6) | Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Myeloblastic... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Refractory Anemia | Myelodysplastic Syndrome With Ring Sideroblasts

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States

Clinical Trials on Anemia in Myelodysplastic Syndromes in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations